These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30975390)

  • 41. Learning from games: stakeholders' experiences involved in local health policy.
    Spitters HPEM; van de Goor LAM; Lau CJ; Sandu P; Eklund Karlsson L; Jansen J; van Oers JAM
    J Public Health (Oxf); 2018 Mar; 40(suppl_1):i39-i49. PubMed ID: 29538724
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Setting the future policy agenda for health technology assessment: a specialty mapping approach.
    Shepherd J; Briggs J; Payne L; Packer C; Kerridge L; Ashton-Key M
    Int J Technol Assess Health Care; 2007; 23(4):405-13. PubMed ID: 17937827
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
    Frønsdal K; Pichler F; Mardhani-Bayne L; Henshall C; Røttingen JA; Mørland B; Klemp M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):374-81. PubMed ID: 23062516
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stakeholders' views on the ethical challenges of pragmatic trials investigating pharmaceutical drugs.
    Kalkman S; van Thiel GJ; Grobbee DE; Meinecke AK; Zuidgeest MG; van Delden JJ;
    Trials; 2016 Aug; 17(1):419. PubMed ID: 27550379
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management information systems for community based interventions to improve health: qualitative study of stakeholder perspectives.
    Penn L; Goffe L; Haste A; Moffatt S
    BMC Public Health; 2019 Jan; 19(1):105. PubMed ID: 30674289
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison analysis. Critics questioning design of effectiveness studies.
    DoBias M
    Mod Healthc; 2009 Feb; 39(8):10. PubMed ID: 19274822
    [No Abstract]   [Full Text] [Related]  

  • 47. Developing Sexual and Reproductive Health Educational Resources for Young Women with Cystic Fibrosis: A Structured Approach to Stakeholder Engagement.
    Kazmerski TM; Miller E; Sawicki GS; Thomas P; Prushinskaya O; Nelson E; Hill K; Miller A; Jean Emans S
    Patient; 2019 Apr; 12(2):267-276. PubMed ID: 30361885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Towards universal coverage: a policy analysis of the development of the National Health Insurance Scheme in Nigeria.
    Onoka CA; Hanson K; Hanefeld J
    Health Policy Plan; 2015 Nov; 30(9):1105-17. PubMed ID: 25339634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Managed competition in the Netherlands-a qualitative study.
    Heinemann S; Leiber S; Gress S
    Health Policy; 2013 Feb; 109(2):113-21. PubMed ID: 23031431
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The discordance between evidence and health policy in the United States: the science of translational research and the critical role of diverse stakeholders.
    Malekinejad M; Horvath H; Snyder H; Brindis CD
    Health Res Policy Syst; 2018 Aug; 16(1):81. PubMed ID: 30115085
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interactions between health technology assessment, coverage, and regulatory processes: emerging issues, goals, and opportunities.
    Henshall C; Mardhani-Bayne L; Frønsdal KB; Klemp M
    Int J Technol Assess Health Care; 2011 Jul; 27(3):253-60. PubMed ID: 21756413
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Community views and perspectives on public engagement in health technology assessment decision making.
    Wortley S; Tong A; Howard K
    Aust Health Rev; 2017 Mar; 41(1):68-74. PubMed ID: 27050156
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of a comprehensive model for stakeholder management in mental healthcare.
    Bierbooms J; Van Oers H; Rijkers J; Bongers I
    J Health Organ Manag; 2016 Jun; 30(4):630-47. PubMed ID: 27296883
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conditional reimbursement within the Dutch drug policy.
    Niezen M; de Bont A; Stolk E; Eyck A; Niessen L; Stoevelaar H
    Health Policy; 2007 Nov; 84(1):39-50. PubMed ID: 17207886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An evaluation of managed access agreements in England based on stakeholder experience.
    Farmer C; Barnish MS; Trigg LA; Hayward S; Shaw N; Crathorne L; Strong T; Groves B; Spoors J; Melendez Torres GJ
    Int J Technol Assess Health Care; 2023 Jul; 39(1):e55. PubMed ID: 37497570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
    Hao Y; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):447-54. PubMed ID: 23977973
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A roadmap to parity in mental health financing: the case of Lebanon.
    Yehia F; Nahas Z; Saleh S
    J Ment Health Policy Econ; 2014 Sep; 17(3):131-41. PubMed ID: 25543116
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CONTRIBUTION OF STAKEHOLDER ENGAGEMENT TO THE IMPACT OF A HEALTH TECHNOLOGY ASSESSMENT: AN IRISH CASE STUDY.
    Ryan M; Moran PS; Harrington P; Murphy L; O'Neill M; Whelan M; Teljeur C
    Int J Technol Assess Health Care; 2017 Jan; 33(4):424-429. PubMed ID: 29032786
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Partnerships for Policy Development: A Case Study From Uganda's Costed Implementation Plan for Family Planning.
    Lipsky AB; Gribble JN; Cahaelen L; Sharma S
    Glob Health Sci Pract; 2016 Jun; 4(2):284-99. PubMed ID: 27353621
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Critical factors that affect the functioning of a research and evaluation capacity building partnership: A causal loop diagram.
    Tobin R; Crawford G; Hallett J; Maycock BR; Lobo R
    PLoS One; 2022; 17(1):e0262125. PubMed ID: 35025924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.